



Express Mail. No.: EV 335 860 122 US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Zhengming CHEN and Laykea TAFESSE Confirmation No.: 5169
Serial No.: 10/669,875 Art Unit: 1614
Filed: September 23, 2003 Examiner: To Be Assigned
Title: THERAPEUTIC AGENTS USEFUL FOR Attorney Docket No: 6750-195-999
TREATING PAIN (CAM NO.: 305158-999193)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

Enclosures accompanying this Information Disclosure Statement are:

1. A List of References Cited by Applicants (References **A01-A67**); and
2. A legible copy of:
 - 2a. Each U.S. patent application publication and U.S. and foreign patent;
 - 2b. Each publication or that portion that caused it to be listed on the Form PTO-1449;
 - 2c. English language abstracts of the non-English language publications; and
 - 2d. All other information or portion that caused it to be listed on the Form PTO-1449.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. Should the U.S. Patent and Trademark Office determine otherwise, the Commissioner is authorized to charge any required fee to Jones Day Deposit Account No. 503013.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: April 5, 2004


Samuel B. Abrams by
George A. Smith 42140
30,605

Samuel B. Abrams (Reg. No.)

JONES DAY

222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
305158-999193
(Formerly 6750-195-999)

APPLICATION NO.
10/669,875

APPLICANT
CHEN et al.

FILING DATE
09-23-03

GROUP
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,039,680	08-13-91	Imperato et al.	514	304	
	A02	5,075,341	12-24-91	Mendelson et al.	514	282	
	A03	5,198,459	03-30-93	Imperato et al.	514	397	
	A04	5,232,934	08-03-93	Downs	514	345	
	A05	5,556,837	09-17-96	Nestler et al.	514	21	
	A06	5,556,838	09-17-96	Mayer et al.	514	25	
	A07	5,574,052	11-12-96	Rose et al.	514	343	
	A08	5,762,925	06-09-98	Sagen	424	93.7	
	A09	6,109,269	08-29-00	Rise et al.	128	898	
	A10	6,204,284	03-20-01	Beer et al.	514	412	
	A11	5,922,872	07-13-99	Cook et al.	544	368	
	A12	5,473,072	12-05-95	Mezei et al.	544	295	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A13	EP 0 634 411 A	01-18-95	EPO			XX	
	A14	JP 06 310786 A	01-18-88	Japan			XX	
	A15	WO 99/37304	07-29-99	PCT				
	A16	WO 02/08221 A2	01-31-02	PCT				
	A17	WO 02/16318 A1	02-28-02	PCT				
	A18	WO 02/072536 A1	09-19-02	PCT				
	A19	WO 02/076946 A2	10-03-02	PCT				
	A20	WO 02/076946 A3	10-03-02	PCT				

OTHER REFERENCES *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A21	Bartho et al., "Involvement of Capsaicin-Sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation," <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 342:666-670 (1990)
	A22	Berkow et al., "The Merck Manual of Medical Information," pp. 345-350, 1997.
	A23	Berkow et al., "The Merck Manual of Medical Information," pp. 352-355, 1997.
	A24	Berkow et al., "The Merck Manual of Medical Information," pp. 496-500, 1997.
	A25	Berkow et al., "The Merck Manual of Medical Information," pp. 525-526, 1997.
	A26	Berkow et al., "The Merck Manual of Medical Information," pp. 528-530, 1997.
	A27	Berkow et al., "The Merck Manual of Medical Information," pp. 530-532, 1997.
	A28	Berkow et al., "The Merck Manual of Medical Information," pp. 631-634, 1997.
	A29	Buchwald et al., "Long-term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis," <i>Surgery</i> 88:507 (1980)
	A30	Chiamulera et al., "Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Mice," <i>Nature Neuroscience</i> 4(9):873-874 (2001)
	A31	Cooke, "Glycopyrrolate in Bladder Dysfunction," <i>SA Medical Journal</i> , 63:3 (1983)
	A32	D'Amour et al., "A Method for Determining Loss of Pain Sensation," <i>J. Pharmacol. Exp. Ther.</i> 72:74-79 (1941)
	A33	Di Marzo et al., "Endovanilloid Signaling in Pain," <i>Current Opinion in Neurobiology</i> 12:372-379 (2002)
	A34	Dogrul et al., Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, a Metabotropic Glutamate Receptor (mGluR ₅) Antagonist, in Experimental Neuropathic Pain in Rats," <i>Neuroscience Letters</i> 292(2):115-118 (2000)
	A35	During et al., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," <i>Ann. Neurol.</i> 25:351 (1989)
	A36	Foley, "Pain" Cecil Textbook of Medicine, pp. 100-107, (1996)
	A37	Fundytus et al., "Antisense Oligonucleotide Knockdown of mGluR ₁ Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation," <i>Pharmacology, Biochemistry & Behavior</i> 73:401-410 (2002)
	A38	Fundytus et al., "Effect of Activity at Metabotropic, as well as Ionotropic (NMDA), Glutamate Receptors on Morphine Dependence," <i>British Journal of Pharmacology</i> 113:1215-20 (1994)
	A39	Fundytus et al., " <i>In Vivo</i> Antinociceptive Activity of Anti-Rat mGluR ₁ and mGluR ₅ Antibodies in Rats," <i>NeuroReport</i> 9:731-735 (1998)
	A40	Fundytus et al., "Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR ₁) Alleviates Pain and Restores Opioid Efficacy After Nerve Injury in Rats," <i>British Journal of Pharmacology</i> 132:354-367 (2001)
	A41	Fundytus, "Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain," <i>CNS Drugs</i> 15:29-58, (2001)
	A42	Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (L. Brunton, author; J. Hardman and L. Limbird eds., 9 th ed. 1996).
	A43	Hargreaves et al., "A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia," <i>Pain</i> 32(1):77-88 (1988)
	A44	Herzog et al., "Urinary Incontinence: Medical and Psychosocial Aspects," <i>Annu. Rev. Gerontol. Geriatr.</i> 9:74-119, (1989)
	A45	Howard et al., "Intracerebral Drug eliveryn in Rats with Leision-Induced Memory Deficits," <i>J. Neurosurg.</i> 71:105 (1989)
	A46	Jhamandas et al., "Spinal Amino Acid Release and Precipitated Withdrawal in Rats Chronically Infused with Spinal Morphine," <i>The Journal of Neuroscience</i> 16(8):2758-66 (April 15, 1996)
	A47	Kim, "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat," <i>Pain</i> 50(3):355-363 (1992)
	A48	Komissarov et al., Chemical Abstracts, Columbus, Ohio, US, abstract no. 115:105837z: "Anxiolytic Activity of 1-(2-Pyrimidinyl) Piperazine Deriv.," <i>Khim.-Farm. Zh.</i> , vol. 25, no. 3, 1991, pages 40-42, USSR (and English language abstract)
	A49	Langer, "New Methods of Drug Delivery," <i>Science</i> 249:1527-1533 (1990)

A50	Levin et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder," The Journal of Urology, 128:396-398 (1982)
A51	Levy et al., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," Science 228:190 (1985)
A52	Masu et al., "Sequence and Expression of a Metabotropic Glutamate Receptor," Nature, 349:760-765 (1991)
A53	Miller et al., "Growth Factor Upregulation of a Phosphoinositide-Coupled Metabotropic Glutamate Receptor in Cortical Astrocytes", The Journal of Neuroscience 15(9):6103-6109 (1995)
A54	Mirakhur et al., "Glycopyrrrolate: Pharmacology and Clinical Use," Anaesthesia 38:1195-1204 (1983)
A55	Ossowska et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-Like Effects in Rats," Neuropharmacology 41:413-420 (2001)
A56	Langer et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983)
A57	Resnick, "Urinary Incontinence," Lancet 346:94-99 (1995)
A58	Saudek et al., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," N. Engl. J. Med. 321:574 (1989)
A59	Sefton, "Implantable Pumps," CRC Crit. Ref. Biomed. Eng. 14:201 (1987)
A60	Seltzer et al., "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury," Pain 43:205-218 (1990)
A61	Sharif et al., "Attenuation of Morphine Tolerance After Antisense Oligonucleotide Knock-Down of Spinal mGluR1," British Journal of Pharmacology 136:865-72 (2002)
A62	Spooren et al., "Novel Allosteric Antagonists Shed Light on mglu ₅ Receptors and CNS Disorders," Trends in Pharmacological Sciences, 22(7):331-337 (2001)
A63	Stein, "Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds," Pharmacology Biochemistry and Behavior 31:451-455 (1988)
A64	Tatarczynska et al., "Potential Anxiolytic- and Antidepressant-Like Effects of MPEP, a Potent, Selective and Systemically Active mGlu5 Receptor Antagonist," British Journal of Pharmacology 132(7):1423-1430 (2001)
A65	Treit, "Animal Models for the Study of Anti-Anxiety Agents: A Review," Neuroscience & Biobehavioral Reviews 9(2):203-222 (1985)
A66	Walker et al., "Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. I. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain," Neuropharmacology 40:1-9 (2001)
A67	Wein, "Pharmacology of Incontinence," Urologic Clinics of North America, 22(3):557-577 (1995)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 ; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 305158-999193 (Formerly 6750-195-999)	APPLICATION NO. 10/669,875
	APPLICANT CHEN et al.	
	FILING DATE 09-23-03	GROUP 1614



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	5,039,680	08-13-91	Imperato et al.	514	304	
	A02	5,075,341	12-24-91	Mendelson et al.	514	282	
	A03	5,198,459	03-30-93	Imperato et al.	514	397	
	A04	5,232,934	08-03-93	Downs	514	345	
	A05	5,556,837	09-17-96	Nestler et al.	514	21	
	A06	5,556,838	09-17-96	Mayer et al.	514	25	
	A07	5,574,052	11-12-96	Rose et al.	514	343	
	A08	5,762,925	06-09-98	Sagen	424	93.7	
	A09	6,109,269	08-29-00	Rise et al.	128	898	
	A10	6,204,284	03-20-01	Beer et al.	514	412	
	A11	5,922,872	07-13-99	Cook et al.	544	368	
	A12	5,473,072	12-05-95	Mezei et al.	544	295	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	A13	EP 0 634 411 A	01-18-95	EPO			XX	
	A14	JP 06 310786 A	01-18-88	Japan			XX	
	A15	WO 99/37304	07-29-99	PCT				
	A16	WO 02/08221 A2	01-31-02	PCT				
	A17	WO 02/16318 A1	02-28-02	PCT				
	A18	WO 02/072536 A1	09-19-02	PCT				
	A19	WO 02/076946 A2	10-03-02	PCT				
	A20	WO 02/076946 A3	10-03-02	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A21	Bartho et al., "Involvement of Capsaicin-Sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation," Naunyn-Schmiedeberg's Archives of Pharmacology, 342:666-670 (1990)
A22	Berkow et al., "The Merck Manual of Medical Information," pp. 345-350, 1997.
A23	Berkow et al., "The Merck Manual of Medical Information," pp. 352-355, 1997.
A24	Berkow et al., "The Merck Manual of Medical Information," pp. 496-500, 1997.
A25	Berkow et al., "The Merck Manual of Medical Information," pp. 525-526, 1997.
A26	Berkow et al., "The Merck Manual of Medical Information," pp. 528-530, 1997.
A27	Berkow et al., "The Merck Manual of Medical Information," pp. 530-532, 1997.
A28	Berkow et al., "The Merck Manual of Medical Information," pp. 631-634, 1997.
A29	Buchwald et al., "Long-term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis," Surgery 88:507 (1980)
A30	Chiamulera et al., "Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Mice," Nature Neuroscience 4(9):873-874 (2001)
A31	Cooke, "Glycopyrrolate in Bladder Dysfunction," SA Medical Journal, 63:3 (1983)
A32	D'Amour et al., "A Method for Determining Loss of Pain Sensation," J. Pharmacol. Exp. Ther. 72:74-79 (1941)
A33	Di Marzo et al., "Endovanilloid Signaling in Pain," Current Opinion in Neurobiology 12:372-379 (2002)
A34	Dogrul et al., Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, a Metabotropic Glutamate Receptor (mGluR ₅) Antagonist, in Experimental Neuropathic Pain in Rats," Neuroscience Letters 292(2):115-118 (2000)
A35	During et al., "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," Ann. Neurol. 25:351 (1989)
A36	Foley, "Pain" Cecil Textbook of Medicine, pp. 100-107, (1996)
A37	Fundytus et al., "Antisense Oligonucleotide Knockdown of mGluR ₁ Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation," Pharmacology, Biochemistry & Behavior 73:401-410 (2002)
A38	Fundytus et al., "Effect of Activity at Metabotropic, as well as Ionotropic (NMDA), Glutamate Receptors on Morphine Dependence," British Journal of Pharmacology 113:1215-20 (1994)
A39	Fundytus et al., "In Vivo Antinociceptive Activity of Anti-Rat mGluR ₁ and mGluR ₅ Antibodies in Rats," NeuroReport 9:731-735 (1998)
A40	Fundytus et al., "Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR ₁) Alleviates Pain and Restores Opioid Efficacy After Nerve Injury in Rats," British Journal of Pharmacology 132:354-367 (2001)
A41	Fundytus, "Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain," CNS Drugs 15:29-58, (2001)
A42	Goodman and Gillman's The Pharmaceutical Basis of Therapeutics 506, 901-915 (L. Brunton, author; J. Hardman and L. Limbird eds., 9 th ed. 1996).
A43	Hargreaves et al., "A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous Hyperalgesia," Pain 32(1):77-88 (1988)
A44	Herzog et al., "Urinary Incontinence: Medical and Psychosocial Aspects," Annu. Rev. Gerontol. Geriatr. 9:74-119, (1989)
A45	Howard et al., "Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits," J. Neurosurg. 71:105 (1989)
A46	Jhamandas et al., "Spinal Amino Acid Release and Precipitated Withdrawal in Rats Chronically Infused with Spinal Morphine," The Journal of Neuroscience 16(8):2758-66 (April 15, 1996)
A47	Kim, "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat," Pain 50(3):355-363 (1992)
A48	Komissarov et al., Chemical Abstracts, Columbus, Ohio, US, abstract no. 115:105837z: "Anxiolytic Activity of 1-(2-Pyrimidinyl) Piperazine Deriv.," Khim.-Farm. Zh., vol. 25, no. 3, 1991, pages 40-42, USSR (and English language abstract)
A49	Langer, "New Methods of Drug Delivery," Science 249:1527-1533 (1990)

A50	Levin et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder," The Journal of Urology, 128:396-398 (1982)
A51	Levy et al., "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," Science 228:190 (1985)
A52	Masu et al., "Sequence and Expression of a Metabotropic Glutamate Receptor," Nature, 349:760-765 (1991)
A53	Miller et al., "Growth Factor Upregulation of a Phosphoinositide-Coupled Metabotropic Glutamate Receptor in Cortical Astrocytes", The Journal of Neuroscience 15(9):6103-6109 (1995)
A54	Mirakhur et al., "Glycopyrrolate: Pharmacology and Clinical Use," Anaesthesia 38:1195-1204 (1983)
A55	Ossowska et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Produces Antiparkinsonian-Like Effects in Rats," Neuropharmacology 41:413-420 (2001)
A56	Langer et al., "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review," J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983)
A57	Resnick, "Urinary Incontinence," Lancet 346:94-99 (1995)
A58	Saudek et al., "A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery," N. Engl. J. Med. 321:574 (1989)
A59	Sefton, "Implantable Pumps," CRC Crit. Ref. Biomed. Eng. 14:201 (1987)
A60	Seltzer et al., "A Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic Nerve Injury," Pain 43:205-218 (1990)
A61	Sharif et al., "Attenuation of Morphine Tolerance After Antisense Oligonucleotide Knock-Down of Spinal mGluR1," British Journal of Pharmacology 136:865-72 (2002)
A62	Spooren et al., "Novel Allosteric Antagonists Shed Light on mglu ₅ Receptors and CNS Disorders," Trends in Pharmacological Sciences, 22(7):331-337 (2001)
A63	Stein, "Unilateral Inflammation of the Hindpaw in Rats as a Model of Prolonged Noxious Stimulation: Alterations in Behavior and Nociceptive Thresholds," Pharmacology Biochemistry and Behavior 31:451-455 (1988)
A64	Tatarczynska et al., "Potential Anxiolytic- and Antidepressant-Like Effects of MPEP, a Potent, Selective and Systemically Active mGlu ₅ Receptor Antagonist," British Journal of Pharmacology 132(7):1423-1430 (2001)
A65	Treit, "Animal Models for the Study of Anti-Anxiety Agents: A Review," Neuroscience & Biobehavioral Reviews 9(2):203-222 (1985)
A66	Walker et al., "Metabotropic Glutamate Receptor Subtype 5 (mGlu ₅) and Nociceptive Function. I. Selective Blockade of mGlu ₅ Receptors in Models of Acute, Persistent and Chronic Pain," Neuropharmacology 40:1-9 (2001)
A67	Wein, "Pharmacology of Incontinence," Urologic Clinics of North America, 22(3):557-577 (1995)

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	